Company

Faron Pharmaceuticals OY

Headquarters: Turku, Finland

Employees: 24

CEO: Dr. Markku Tapani Jalkanen

OMXH: FARON

Market Cap

€119.1 Million

EUR as of July 1, 2024

US$127.9 Million

Market Cap History

Faron Pharmaceuticals OY market capitalization over time

Evolution of Faron Pharmaceuticals OY market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Faron Pharmaceuticals OY

Detailed Description

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Financials

Last Financial Reports Date Dec. 31, 2023
Revenue TTM €0
EBITDA €-28,371,000
Gross Profit TTM €0
Profit Margin 0.00%
Operating Margin 0.00%
Quarterly Revenue Growth %
Financial Reports & Statistics

Stocks & Indices

Faron Pharmaceuticals OY has the following listings and related stock indices.


Stock: OMXH: FARON wb_incandescent

Stock: LSE: FARN wb_incandescent

Details

Headquarters:

Joukahaisenkatu 6

Intelligate

Turku, 20520

Finland

Phone: 358 2469 5151

Fax: 358 2469 5152